Reports Q3 revenue $1.16M, consensus $1.12M. “During the third quarter, Dyadic completed its strategic pivot from a research and development-driven company to a commercially focused biotechnology solutions provider underpinned by our protein production platforms,” said Joe Hazelton, president and COO of Dyadic. “With our comprehensive rebranding, redesigned website optimized for commercial engagement and investor relations, and the addition of CRISPR technology through our ERS Genomics license, we are strengthening the foundation for scalable growth.” Mr. Hazelton concluded, “Our third-quarter achievements demonstrate the successful execution of our strategic transformation to a commercial biotech leader. With enhanced capabilities from our CRISPR license, growing commercial traction, and a strengthened financial foundation, we believe Dyadic is well positioned for sustainable revenue growth and long-term value creation.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYAI:
- Dyadic International, ERS Genomics announces CRISPR/Cas9 license
- Dyadic International Inc. (DYAI) Q3 Earnings Cheat Sheet
- Dyadic International assumed with a Buy at H.C. Wainwright
- Dyadic International Achieves Milestone Payments and Compliance
- Dyadic International announces achievement of milestone payments